September 2026– date –
-
BioNTech and Genentech Terminate Phase 2 Personalized Cancer Vaccine Trial Due to Survival Imbalance
Fierce Biotech USA Overview BioNTech and Genentech have cancelled their Phase 2 clinical trial for autogene cevumeran (BNT122), a personalized cancer vaccine targeting colorectal cancer patients, after an independent data safety monitori... -
Novartis Halts Autoimmune CAR-T Trials After Three Patient Deaths, Sparking Safety Debate
Endpoints News USA Overview Novartis has disclosed the deaths of three patients from immune effector cell-associated hemophagocytic lymphohistiocytosis (IEC-HS) complications in clinical trials of its CAR-T cell therapy, rapcabtagene aut... -
Winship Cancer Institute Launches Cellular Therapy Initiative to Scale Next-Gen Cancer Treatment Development
Winship Cancer Institute USA Overview Winship Cancer Institute has launched a "Cellular Therapy Initiative" to accelerate the development of next-generation cancer treatments, including expansion of its cGMP manufacturing capabilities. T... -
Ultragenyx’s Phase 3 Angelman Syndrome Trial Fails, Triggering 43% Stock Plunge
Fierce Biotech USA Overview Ultragenyx reported that its investigational asset apazunersen failed to meet primary and secondary endpoints in the Phase 3 Aspire trial for Angelman syndrome, leading to a dramatic 43% drop in the company's ... -
Northway Biotech Launches €61M Cell Therapy CDMO in Lithuania, Scaling Advanced Biologics for Global Demand
PR Newswire (Northway Biotech) Lithuania Overview Northway Biotech has inaugurated a state-of-the-art €61 million cell therapy and personalized medicine CDMO facility in Vilnius, Lithuania. This 3,500-square-meter site boasts up to 20 in... -
3D Bioprinting Market Drives Regenerative Medicine and Biomedical Innovation, Accelerated by AI Integration
The Business Research Company Global Overview The 3D bioprinting market is rapidly growing as a pivotal technology driving innovation in regenerative medicine and biomedical fields. This technology combines living cells, biomaterials, an... -
TScan Therapeutics Pivots to In Vivo TCR-T for Solid Tumors, Cuts 75% of Staff
BioPharm International USA Overview TScan Therapeutics announced a strategic pivot toward in vivo gene-edited TCR-T cell therapy for solid tumors, accompanied by a reduction of approximately 75% of its workforce. The company will halt it... -
T-MAXIMUM Allogeneic CAR T-Therapy MT027 Receives FDA Fast Track Designation for Recurrent Glioblastoma
PR Newswire USA Overview T-MAXIMUM PHARMACEUTICAL announced that its B7-H3-targeted allogeneic CAR T-cell therapy, MT027, has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of recurrent glioblastoma. MT027 had ... -
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
Panasonic and Kyoto University CiRA Foundation Develop Fully Automated iPSC Establishment System to Accelerate Regenerative Medicine Adoption
Panasonic Holdings (Facebook post) Japan Overview Panasonic Holdings and the Kyoto University iPS Cell Research Institute (CiRA) Foundation have collaboratively developed a groundbreaking automated system for establishing iPS cells from ...
